249 related articles for article (PubMed ID: 23765756)
1. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant.
Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F
Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756
[TBL] [Abstract][Full Text] [Related]
2. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
6. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.
Starke RM; Raper DM; Payne SC; Vance ML; Oldfield EH; Jane JA
J Clin Endocrinol Metab; 2013 Aug; 98(8):3190-8. PubMed ID: 23737543
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
9. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant: Balance after 10 years.
Bernabeu I; Marazuela M
Endocrinol Nutr; 2015 Oct; 62(8):363-5. PubMed ID: 26242927
[No Abstract] [Full Text] [Related]
12. Transsphenoidal surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations.
Zada G; Cavallo LM; Esposito F; Fernandez-Jimenez JC; Tasiou A; De Angelis M; Cafiero T; Cappabianca P; Laws ER
Neurosurg Focus; 2010 Oct; 29(4):E8. PubMed ID: 20887133
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
14. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
15. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
[TBL] [Abstract][Full Text] [Related]
16. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly.
Bellut D; Hlavica M; Schmid C; Bernays RL
Neurosurg Focus; 2010 Oct; 29(4):E9. PubMed ID: 20887134
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
20. Recent results of secondary transnasal surgery for residual or recurring acromegaly.
Abe T; Lüdecke DK
Neurosurgery; 1998 May; 42(5):1013-21; discussion 1021-2. PubMed ID: 9588545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]